The QualityStocks Daily Tuesday, August 7th, 2019

Today's Top 3 Investment Newsletters

PoliticsAndMyPortfolio (ARPC) +231.52%

QualityStocks (RGBP) +200.00%

PennyStockLocks (GETH) +48.15%

The QualityStocks Daily Stock List

Calfrac Well Services Ltd. (CFWFF)

StockScores, Stock Target Advisor, CapitalCube, Street Insider, Investors Hangout, MarketBeat, and Morningstar reported earlier on Calfrac Well Services Ltd. (CFWFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Calfrac Well Services Ltd. is one of the largest hydraulic fracturing companies globally. It has a combined fleet of 1.3 million horsepower. Calfrac is a leading independent worldwide provider of specialized oilfield services. The Company offers hydraulic fracturing, coiled tubing, cementing, other well stimulation, and pressure pumping services to oil and natural gas industries. Established in 1999, Calfrac Well Services lists on the OTC Markets. The Company is based in Calgary, Alberta.

Calfrac is an API Q2 certified company. It operates in western Canada, the U.S., Russia and Argentina. The design of its services are to help increase the production of oil and natural gas. The Company’s primary business is the provision of hydraulic fracturing services. Since its inception in 1999, Calfrac has established itself as an important energy services provider. It has an expanded geographic network and an operating fleet sized correctly to service the markets where it operates.

Regarding Cementing, Calfrac cement testing labs are state-of-the-art. The Company offers primary and remedial cementing services in a variety of wells. Calfrac utilizes diverse classes of conventional and special cements, as well as specially developed cementing systems. Its in-house cementing experts developed proprietary lightweight and ultra-lightweight cementing systems that use unconventional cement without the use of extenders.

Pertaining to Coiled Tubing, Calfrac’s fleet of coiled tubing equipment provides services from shallow through deep -below 10,000 ft. (3,000 m) true vertical depth, with reel capacities up to 24,000 ft. (7,200 m) for 2 3/8 inches (60.3 mm) coiled tubing . It covers most of today’s wells. This includes long-leg multi-stage fractured horizontals drilled in deep shales and tight sands.

Concerning Hydraulic Fracturing, the Company is a full service hydraulic fracturing provider. It provides slickwater solutions for fresh and high TDS brine applications, leading support for high viscosity friction reducer fracture fluid systems, along with all traditional industry applications of gel based, crosslink and energized fracturing needs.

Last week, Calfrac Well Services announced its financial and operating results for the three and six months ended June 30, 2019. During the quarter, the Company pumped close to 1.0 million tons of sand and completed 7,733 fracturing stages in North America. Furthermore, Calfrac completed the acquisition of additional fracturing equipment in Argentina.

Revenue in Q2 of 2019 was $429.6 million. This represents a decrease of 10 percent from the first quarter of 2019, mainly because of lower fracturing activity in Canada resulting from the normal seasonal slowdown during spring break-up. Revenue in the U.S., Russia and Argentina was relatively flat on a sequential basis. Revenue per fracturing job grew by 35 percent due to job mix in Canada and Argentina.

Calfrac Well Services Ltd. (CFWFF), closed Wednesday's trading session at $1.14, off by 6.2346%, on 7,200 volume with 9 trades. The average volume for the last 3 months is 5,684 and the stock's 52-week low/high is $0.0081/$0.0238.

chart

Jaguar Health, Inc. (JAGX)

Stock Twits, Alpha Stock News, Market Screener, Stockwatch, Infront Analytics, Proactive Investors, TradingView, Street Insider, Stockhouse, Investing.com, and Super Stock Screener reported earlier on Jaguar Health, Inc. (JAGX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Jaguar Health, Inc. is a commercial stage pharmaceutical company centered on developing novel, sustainably derived gastrointestinal products on a worldwide basis. The Company’s wholly-owned subsidiary is Napo Pharmaceuticals, Inc. Napo concentrates on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Jaguar Health is headquartered in San Francisco, California.

The Company’s corporate mission is to identify human and animal health market opportunities where it can develop targeted products that take advantage of its extensive intellectual property (IP) portfolio, deep pipeline, and broad botanical library. Jaguar’s focus is naturally derived health solutions for humans and animals worldwide.

Jaguar Health’s Mytesi® (crofelemer) product is approved by the U.S. FDA (Food and Drug Administration) for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. MYTESI® is not indicated for the treatment of infectious diarrhea.

Last week, Jaguar Health announced that Indena S.p.A., one of the two contract manufacturers of the active pharmaceutical ingredient (API) in crofelemer, successfully developed and implemented an improved crofelemer manufacturing process. This effectively increases yield and realizes decreased cost through increased manufacturing efficiencies. This is while keeping the same phytochemical profile without compromising product quality, safety, purity and efficacy.

The modified process enables Jaguar Health's wholly-owned human-health subsidiary, Napo Pharmaceuticals, to support the increased crofelemer manufacturing demand expected if crofelemer receives FDA approval for new indications. This includes approval for the symptomatic relief of cancer therapy-related diarrhea (CTD). Indena (Milan, Italy) is a foremost CDMO provider, with an emphasis on complex small molecules and natural derivatives.

Today, Jaguar Health announced that Napo Pharmaceuticals launched a refreshed version of the Mytesi.com website. The site has been optimized to provide a more patient-centric user experience and help people living with HIV locate resources, which can help them learn about and obtain access to Mytesi. The resources include a patient discussion guide, the Mytesi Copay Savings Card, and a new consumer-friendly infographic that illustrates how Mytesi works.

Jaguar Health, Inc. (JAGX), closed Wednesday's trading session at $1.66, up 4.4025%, on 479,031 volume with 1,945 trades. The average volume for the last 3 months is 469,295 and the stock's 52-week low/high is $2.50/$4.9499998.

chart

alpha-En Corporation (ALPE)

Zacks, Stocksbeat, Invest Tribune, Otc.watch, Market Screener, PR Newswire, 4-Traders, Last10k, InvestorsHub, Wallet Investor, TradingView, and Simply Wall St reported earlier on alpha-En Corporation (ALPE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corporation is an innovative clean technology company listed on the OTC Markets OTCQB. It focuses on enabling next generation battery technologies through developing and bringing to market pure, state of the art materials produced in an environmentally sustainable manner. The Company has developed a patent pending process for the production of lithium metal and associated products produced at room temperature. alpha-En is headquartered in Yonkers, New York.

The Company is enabling next generation energy storage. Its lithium metal is purer than what is presently available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

alpha-En produces its lithium employing a room temperature process (process conducted at 20°-30°C), which does not require or release noxious chemicals. The Company’s process allows for the flexible deposition and intercalation of lithium into custom substrates that streamlines the manufacturing of batteries of all sizes. alpha-En’s novel process is mercury and chlorine free. It eliminates the use and release of toxic chemicals and expensive containment costs. The Company’s electrodeposition method produces thin films of highly pure lithium on a host of substrates.

Strategic partners of alpha-En include Argonne National Laboratory and Princeton University. The Company’s first-rate Scientific Team includes a Nobel Prize winning Chemist.

Last month, alpha-En announced that it received a $1 million technology development grant from the New York State Energy Research and Development Authority (NYSERDA). This funding will help to pay for the considerable amount of research and development (R&D) required to bring disruptive battery technology from the laboratory to final commercialization.

NYSERDA administers many programs and initiatives via its Innovation portfolio to provide entrepreneurs and early-stage companies exclusive access to development partners, investors, as well as talent. On the whole, NYSERDA is deploying $800 million over 10 years as direct investments and commercialization support for early-stage ventures.

Mr. Jerome Feldman, Executive Chairman of alpha-En, said, "We are delighted and honored that NYSERDA has chosen our patented and proprietary technology to be worthy of its support. This is another milestone for our company in its mission to change the way energy is stored and utilized.”

alpha-En Corporation (ALPE), closed Wednesday's trading session at $1.05, up 2.79%, on 150 volume with 2 trades. The average volume for the last 3 months is 10,192 and the stock's 52-week low/high is $0.560000002/$11.0500001.

chart

Bionik Laboratories Corp. (BNKL)

Zacks, Business Wire, Stockhouse, Wallet Investor, The Street, Seeking Alpha, MarketWatch, InvestorsHub, and PR Newswire reported previously on Bionik Laboratories Corp. (BNKL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bionik Laboratories Corp. focuses on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home. A robotics company, it has three products on the market and four products in different stages of development. These products are focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients. Bionik Laboratories has its head office in Toronto, Ontario and has its U.S. headquarters in Watertown, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

Bionik’s family of robotic rehabilitation products are the result of pioneering medical engineering research and development (R&D) at the Newman Laboratory for Biomechanics and Human Rehabilitation at the Massachusetts Institute of Technology (MIT). The Company’s products include InMotion ARM ™; InMotion HAND™, and InMotion WRIST™. InMotionRobots™ are for all stages of recovery – from acute to chronic. Bionik Laboratories has its newest generation InMotion ARM/HAND™ robotic system for clinical rehabilitation of stroke survivors and those with mobility impairments due to neurological conditions.

The design of Bionik Laboratories’ modular systems approach to neurorehabilitation is to optimize the use of robotics in a way consistent with the most modern clinical research and neuroscience. This is while considering the latest understanding on motor learning interference and motor memory consolidation.

Bionik’s robotic products have excellent capacity for measurement and immediate interactive response. These products sense the patient’s movement and respond to a patient’s continually-changing ability. In addition, robots guide the exercise treatment accordingly and provide quantifiable feedback on progress and performance. Furthermore, if the patient cannot move, the robot gently assists the patient to initiate movement towards the target.

This past May, Bionik Laboratories announced the completion of a landmark Robot Assisted Training for the Upper Limb after Stroke (RATULS) trial using the Company’s InMotion Robotic Therapy Systems. Results of the RATULS trial were presented at the European Stroke Organisation Conference (ESOC) in Milan, Italy on May 22, 2019 and published in the Lancet Online Journal on the same day.

The study’s purpose was to compare clinical effectiveness of robot assisted training, enhanced upper limb therapy, and usual care for patients with moderate or severe upper limb functional limitation. The RATULS trial started in 2014. It was completed at the end of 2018.

Dr. Eric Dusseux, Chief Executive Officer of Bionik Laboratories, said, “We are pleased that the RATULS trial confirmed the finding of previous research studies which demonstrated that robot-assisted therapy improved upper limb impairment when compared with conventional care methods for stroke victims. The trial’s finding that robotic therapy is the only therapy to statistically maintain a significant impairment advantage at six months after treatment is a strong signal that robotic therapy is critical for achieving positive patient outcomes.”

Recently, Bionik Laboratories announced financial results for the fiscal year ended March 31, 2019. The Company reported Sales of $3,246,038. This represents an increase of 229 percent versus the reported Sales of $987,431 in the previous fiscal year.

Bionik Laboratories Corp. (BNKL), closed Wednesday's trading session at $3.19, even for the day, on 320 volume. The average volume for the last 3 months is 93 and the stock's 52-week low/high is $0.025699999/$1.51999998.

chart

Cuentas, Inc. (CUEN)

Wallet Investor, PR Newswire, Investing.com, Stockhouse, Simply Wall St, InvestorsHub, and GlobeNewswire reported beforehand on Cuentas, Inc. (CUEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cuentas, Inc. is a foremost FinTech (Financial Technology) provider of mobile banking and payment solutions serving Latino and Hispanic consumers. The Company uses technical innovation together with existing and emerging technologies to deliver accessible, efficient and reliable mobile, new-era and traditional financial services to consumers. Cuentas has its proprietary Cuentas General Purpose Reloadable (GPR) Card. OTCQB-listed, Cuentas is headquartered in Miami, Florida.

Fundamentally, Cuentas uses technology to bridge the gap between traditional financial services and the underbanked U.S. Latino population. Cuentas’ services include, but are not limited to, mobile banking, online banking, prepaid debit, bill pay, ACH and mobile deposits, cash remittance, peer to peer money transfer, and bank accounts to customers who previously could not get bank accounts.

The Cuentas General Purpose Reloadable (GPR) Card provides holders with digital wallets, discounts for purchases at major physical and online retailers, free telecom, and the ability to buy digital content. The card will be available in more than 31,000 bodegas. The pioneering Cuentas FinTech card will launch in New York City in Q3 of 2019.

The Cuentas Fintech Card is an online bank account integrated with the Cuentas branded general purpose reloadable card (GPR). It offers a complete online banking solution to all, including those without a U.S. government issued ID. Regarding Mobile Wallet, the in-app Mobile Wallet offers FinTech Card functionality for online and mobile purchases.

The Cuentas Virtual Marketplace offers discounted gift cards to Cuentas cardholders. These can be stored in the Cuentas Mobile Wallet and be used online, sent electronically to friends or family, and redeemed for a physical gift card.

Cuentas has partnered with Sutton Bank as the issuing bank for Cuentas' soon to be launched FinTech card. Sutton Bank is an Ohio Chartered FDIC insured bank. Sutton Bank is a leading bank servicing financial technology companies across the nation.

Yesterday, Cuentas announced it closed the earlier announced $2.5 million strategic investment by an accredited FinTech investor. Cuentas has received to date $1.5 million of the $2.5 million committed by the accredited investor. The Company will use the proceeds for marketing and fees associated with the launch of the Cuentas FinTech Card in Q3 of 2019. Cuentas plans to open the New York market initially and then the Los Angeles market as it prepares for its nationwide rollout.

Cuentas, Inc. (CUEN), closed Wednesday's trading session at $2.30, up 22.9947%, on 10,780 volume with 24 trades. The average volume for the last 3 months is 3,676 and the stock's 52-week low/high is $1.22500002/$8.50.

chart

LandStar, Inc. (LDSR)

Zacks, Street Insider, Silicon Investor, TipRanks, Stockwatch, Stockhouse, InvestorsHub, OTC Markets, and Simply Wall St reported beforehand on LandStar, Inc. (LDSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LandStar, Inc. is the parent company of Data443™ Risk Mitigation, Inc., a top data security and privacy company. By way of its wholly-owned subsidiary DATA443™ Risk Mitigation, LandStar enables secure data - across local devices, network, cloud, and databases - at rest and in-flight. Its products and services are central to cyber data security, GDPR, compliance, and also governance capabilities. LandStar is based in Raleigh, North Carolina.

LandStar’s family of products include ArcMail, a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions. Products also include ARALOC™, a market leading secure, cloud-based platform for the management, protection and distribution of digital content to the desktop and mobile devices that protects an organization’s confidential content and intellectual property (IP) assets from leakage - malicious or accidental - without impacting collaboration between all stakeholders.

LandStar’s products also include the WordPress GDPR Framework with greater than 20,000 active users. It allows organizations of all sizes to comply with the GDPR and other privacy frameworks. In addition, products include The Virtual Data Protection Officer program that offers a turnkey and outsourced DPO capability for smaller organizations; and, Data443™ Privacy Manager, which enables the full lifecycle of Data Privacy Access Requests, Remediation, Monitoring and Reporting.

Products additionally include ClassiDocs™, the Company’s award-winning data classification and governance technology, which supports CCPA, LGPD and GDPR compliance; and ClassiDocs™ for Blockchain that provides an active implementation for the Ripple XRP, which protects blockchain transactions from inadvertent disclosure and data leaks.

Last month, LandStar announced continued momentum in its product line with the addition of high-profile new data sources to enable in CCPA, GDPR, eDiscovery, archiving and data retention requirements. The growing platform list of integrations include support for top social media channels including Twitter, Facebook, Instagram and LinkedIn.

Mr. Jason Remillard, Chief Executive Officer and Founder of Data443, said, “The hybrid ArcMail solution is changing the game in the data privacy, compliance and archiving space. We listened and delivered when the market and our customers demanded innovative, expanded archiving options that can easily work within their existing infrastructure without sacrificing compliance or governance capabilities.”

LandStar, Inc. (LDSR), closed Wednesday's trading session at $0.0006, up 20.00%, on 6,370,592 volume with 24 trades. The average volume for the last 3 months is 25,438,897 and the stock's 52-week low/high is $1.21000003/$5.80000019.

chart

West Coast Ventures Group Corp. (WCVC)

All Penny Stocks, TipRanks, Market Screener, Market Wire News, Last10k, Wallet Investor, TradingView, Simply Wall St, InvestorsHub, Stockwatch, Stockhouse, GlobeNewswire, 4-Traders, and PR Newswire reported previously on West Coast Ventures Group Corp. (WCVC), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

West Coast Ventures Group Corp. is America's first CBD restaurant stock under “Illegal Brands”. The Company operates several contemporary restaurant concepts. This includes the flagship Illegal Burger, a quick-casual burger + bar concept. West Coast Ventures’ shares trade on the OTC Markets Group’s OTCQB. The Company has its head office in Denver, Colorado.

West Coast Ventures’ team includes extensive restaurant management experience, business experts from numerous industries, marketing experts and investment experts. Mr. Jim Nixon is the Chief Executive Officer of West Coast Ventures Group Corp. The Company’s holdings include the above-mentioned chain Illegal Burger that Mr. Nixon founded in 2013. Mr. Nixon brings greater than three decades of progressively responsible experience in every aspect of the restaurant business.

Last week, West Coast Ventures Group announced the continued success of its Illegal Brands concepts. The Company has launched its latest restaurant, Illegal Pizza. The first Illegal Pizza restaurant opened in Lauderdale, Florida on June 13, 2019. Illegal Pizza takes what made Illegal Burger popular and refines the concept with build your own pizzas and wide-ranging options for an array of dietary requirements. In addition, the location sells Illegal Brands CBD water and sachets.

The expectation is that this location will bring in approximately $700,000 within the first year. It will be the first of many Illegal Pizza locations across the nation.

Yesterday, West Coast Ventures Group announced that its Illegal Brands CBD offerings continue to grow in popularity and diversity. Two of the Company’s flagship Illegal Burger franchises have already experienced significant success. The IB CitiSet is on pace to surpass $700,000 in sales in its first full year of operations. The IB Writer Square in Downtown Denver is also on pace to surpass $1 million in sales in 2019. West Coast Ventures has turned Illegal Burger into a full fledged franchise offering.

West Coast Ventures Group Corp. (WCVC), closed Wednesday's trading session at $0.047, up 18.6869%, on 275,942 volume with 36 trades. The average volume for the last 3 months is 305,726 and the stock's 52-week low/high is $0.899900019/$2.25.

chart

MMEX Resources Corp. (MMEX)

Discovery Stocks, HydroCarbonProcessing, Investors Hangout, MarketWatch, MicroCapDaily, Stockhouse, Business Wire, 4-Traders, InvestorsHub, Morningstar, OTC Markets, and Wallet Investor reported earlier on MMEX Resources Corp. (MMEX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MMEX Resources Corp. focuses on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas and South America. The Company established to engage in the exploration, extraction, refining and distribution of oil, gas, petroleum products and electric power. A development-stage company, MMEX Resources is headquartered in Fort Stockton, Texas.

MMEX’s main areas of interest include the acquisition and potential development of refining, oil & gas assets in Texas, and the acquisition of oil and gas properties in Peru. In addition, main areas of interest include crude, oil and product export opportunities in Latin America, and the development of terminals, storage, refining, oil & gas in Brazil.

The Company’s projects include the Pecos County Refinery Project, Fort Stockton, Texas. Phase 1 of this project is a 10,000 BPD Crude Distillation Unit. Phase 2 is a 100,000 BPD Large-Scale Refinery. The project is in Sulfur Junction, about 20 miles northeast of Fort Stockton. The project is strategically positioned close to oil production in West Texas, with storage capability.

MMEX Resources signed an off-take agreement with Pilot Thomas Logistics. The off-take agreement is for the sale of its diesel fuel production from Phase 1 of the MMEX refinery project in Pecos County. In November 2017, MMEX Resources broke ground on Phase 1 of the MMEX Refinery Project in Pecos County. The agreement provides for Pilot Thomas Logistics to obtain 100 percent of the diesel production from Phase 1, roughly 4,200 barrels per day, for markets in the Permian Basin area principally for use in drilling operations.

MMEX Resources intends to develop a solar power project to provide electric power to its planned 10,000 barrel-per-day (BPD) crude distillation unit and its full-scale crude oil refinery in Pecos County near Fort Stockton, Texas.

In October 2018, MMEX Resources and Blanchard Industrial, LLC (BIL) announced that BIL will be the overall EPC contractor to complete the detailed engineering and to construct the planned Pecos County Crude Distillation Unit refinery earlier announced by MMEX. BIL is an industry leader in design, engineering, procurement and construction (EPC) solutions.

MMEX Resources Corp. (MMEX), closed Wednesday's trading session at $0.0004, up 33.3333%, on 67,200,175 volume with 34 trades. The average volume for the last 3 months is 13,946,714 and the stock's 52-week low/high is $0.009999999/$0.079999998.

chart

Vitalibis, Inc. (VCBD)

InvestorsHub, Simply Wall St, Morningstar, Investors Hangout, TradingView, 4-Traders, Stockopedia, Stockflare, Stockwatch, Stockhouse, OTC Markets, Market Exclusive, and Street Insider reported earlier on Vitalibis, Inc. (VCBD),  and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Vitalibis, Inc. is a technology-based seller of premium, full spectrum phyto-cannabinoid rich (PCR) products. The Company is also a seller of personal care and organic certified nutritional products formulated with first-class hemp extracts. Vitalibis is working to be an iconic lifestyle brand that promotes health and wellness within the fast-growing medicinal cannabis industry. OTCQB-listed, has its corporate office in Las Vegas, Nevada.

The Company’s focus is selling branded, full spectrum, phyto-cannabinoid rich hemp oil products, cold processed skincare, body care and organic certified nutritional products, which are safe and effective. All of its products are made using cold-processed technology, to minimize heat and harmful ingredients.

Vitalibis has a technology integration agreement to license the state-of-the-art newkleus™ technology to facilitate its micro-influencer sales model and enhance and complement its social media strategy. The agreement grants Vitalibis an exclusive license for the newkleus patent-pending, user-generated content (UGC) technology for all applications in the cannabis industry.

Regarding its products, the Company’s Vitalibis Signature 300 is a full spectrum, phyto-cannabinoid rich (PCR) hemp oil blended with Medium Chain Triglycerides (MCT) from coconut oil. Furthermore, its Vitalibis Daily Wellness capsules are a certified organic super-food specifically formulated to promote overall wellness and balanced health.

Earlier this month, Vitalibis announced that it launched its newest product, the Vitalibis Soothing Body Cream. The Vitalibis Soothing Body Cream contains a number of oils that provide a cooling/warming sensation to targeted areas. It does so while leaving the skin feeling moisturized.

Yesterday, Vitalibis announced that it entered into a Business Alliance Agreement with Aromatics International. Vitalibis will market and sell certain Aromatics International essential oil products within a newly launched Curated Products section of the Vitalibis website.

Mr. Steven Raack, Vitalibis Chief Executive Officer, stated, “Aligning with Aromatics International is an exciting next step for us as we continue to build out our business strategies from a technology and product standpoint. Working with Aromatics International brings to the Vitalibis community high-quality essential oils and associated educational content. We will continue to identify and align with brands focused on product quality, safety and efficacy as we build a movement around personal and environmental wellness.”

Vitalibis, Inc. (VCBD), closed Wednesday's trading session at $0.40, up 33.3333%, on 10,222 volume with 7 trades. The average volume for the last 3 months is 32,001 and the stock's 52-week low/high is $0.019999999/$0.191750004.

chart

Northstar Electronics, Inc. (NEIK)

Penny Stock Tweets, MarketWatch, Stockopedia, Hotstocked, Zacks, InvestorsHub, last10k, Proactive Investors, Financial Buzz, Front Page Stocks, MicroCapSpot, Business Wire, Stockhouse, The Street, YCharts, Capital Cube, Daily Stocks, Marketwired, GuruFocus, Wallet Investor, OTC Watch, and Market Screener reported previously on Northstar Electronics, Inc. (NEIK), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Northstar Electronics, Inc. works in the aviation, defense, and marine industries. The OTCQB-listed Company has a wide-ranging history of developing and manufacturing defense and commercial electronic and mechanical systems. Established in the late 1990’s, Northstar Electronics is headquartered in Virginia Beach, Virginia. Northstar Electronics’ subsidiary is Northstar Sealand Enterprises Ltd. (NSEL).

The Company carried out design and manufacturing contracts for diverse divisions of Lockheed Martin Corp. Additionally, Northstar designed, manufactured, and sold its own sonar-based system to commercial customers.

Northstar Electronics has moved towards making and selling its own independent systems, since the end of the aforementioned contracts. At present, the Company is undergoing restructuring to move forward with a renewed emphasis on the development of a new aviation business and also carry out work to develop unique sonar systems.

Subsidiary NSEL is jointly owned by Northstar Electronics and Sealand Aviation Ltd. Both companies have many years of experience in working with certified commercial aircraft and government military contracts. NSEL is working to acquire the global rights to a “Turbo-Prop” single engine industrial airplane from an international leader in the aerospace industry. The timeline for the final agreement with the subsidiary company that owns the rights to the airplane has been extended.

The chief applications for the airplane are in “Agriculture and Rapid Response Forest Fire Fighting (RRFFF).” NSEL is continuing its evaluation of the “Cloud Seeding” market. Moreover, Northstar sees substantial potential in the field of Counter Insurgency (COIN). Company Management is exploring future possibilities in this sector.

Northstar Electronics is moving ahead with its expansion from being an aerospace contract manufacturer to becoming an “Original Equipment Manufacturer” (OEM) with its own products. The Company made significant progress in the purchase of the worldwide rights to a single engine “Turbo Prop” airplane from a major overseas aerospace company.

Last week, Northstar Electronics provided an update to its shareholders on an important milestone achieved by its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), on a major acquisition. Northstar Electronics and NSEL have been working closely with a major international Aerospace Company with the goal to acquire the international rights and IP (Intellectual Property) for a high-performance Turbo-Prop industrial aircraft.

The Aerospace Company recently presented the main details of this complex transaction to the Canadian government’s Industry, Science and Education Department (ISED). The plan was met with positive and enthusiastic feedback from the department’s representatives.

This confirmation of interest in the transaction, and its eligibility for considerable “Offset” credits under ISED’s Industry Trade and Benefits program, will now accelerate the planned transaction through the Aerospace Company’s internal review processes. Northstar Electronics is moving ahead with its plans to provide financial support for the endeavour. The Company is aligning key investors and financial instruments. NSEL continues its pre-sales efforts and its preparations for a fast and efficient ramp-up to production.

Northstar Electronics, Inc. (NEIK), closed Wednesday's trading session at $0.014, up 55.5556%, on 10,000 volume with 1 trade. The average volume for the last 3 months is 15,000 and the stock's 52-week low/high is $0.0062/$0.05.

chart

Vegalab, Inc. (VEGL)

OTC Markets, GuruFocus, Simply Wall St, YCharts, Investors Hangout, Stockwatch, Capital Cube, InvestorsHub, TradingView, Business Insider, PennyStockHub, Wallet Investor, Barchart, MarketWatch, InvestingNewsAlerts, Stockhouse, and Stockopedia reported earlier on Vegalab, Inc. (VEGL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vegalab, Inc. is the exclusive distributor in North and South America of a line of all-natural, biologically derived pesticides, fertilizers, and specialty agricultural products. Its products support a healthy soil biome. Additionally, they are cost competitive with synthetic chemicals that do just the opposite. The Company’s products include Biocontrol Agents, Insecticides, Fungicides, Soil Inoculants, and Fertilizers. Vegalab has its corporate office in North Palm Beach, Florida.

Vegalab operates in two segments of the food industry. These are the Agronomy Business and the Packing Business. The Agronomy Business involves the manufacture and distribution of all-natural crop protection, crop health, and soil enhancement products. The Packing Business operates a citrus packing facility.

All of the Company’s oil-based products go through a process of micronization. This gives the oils the ability to cover a larger surface area and enables deeper penetration into the crevices of plants, insects, and pathogens. The minute pores and filaments in the plant absorb Vegalab’s products faster versus conventional oils.

Vegalab’s pesticides are highly effective against targeted organisms, non-toxic to beneficial organisms, and safe for the environment. Every Vegalab product strives to enhance productivity and lessen waste.

In October 2017, Vegalab purchased M&G Packing. The facility consists of approximately 11 acres of real property and 30,000 sq. ft. of buildings. In March 2018, Vegalab announced that it completed its acquisition of The Agronomy Group, LLC effective as of February 1, 2018. The Agronomy Group (TAG) is located in Tulare County, California. It is a producer and distributor of environmentally friendly agrochemicals and also distributes other products.

In November 2018, Vegalab announced the acquisition, subject to a lease option agreement that runs through November 1, 2019, of a major fruit packing facility in Lindsay, California. The facility (on 9.4 acres in California’s San Joaquin Valley) comprises greater than 260,000 square feet of working space. This includes three packing lines, roughly 32,000 square feet of cold storage, 12 de-greening rooms, and a 6 bay shipping area.

This facility will significantly increase Vegalab’s present capacity to process and pack fruit. Vegalab’s management team believes the acquisition will boost the Company’s overall fruit processing capacity to more than US $150 million annually. The current capacity at the facility is about 200 bins per hour.

This month, Vegalab announced it will start selling its products via all three locations of Pratum Co-op, a well-known and fast growing agricultural retailer based in the diverse growing region of the Willamette Valley in Oregon. Pratum Co-op is a supplier of fertilizer, crop protection and petroleum products. Pratum has three state of the art locations to serve its members who are prominent growers of grass seeds, blueberries, hazelnuts, grapes, hay, carrot seed and more.

Vegalab, Inc. (VEGL), closed Wednesday's trading session at $1.00, up 35.1351%, on 10,882 volume with 6 trades. The average volume for the last 3 months is 945 and the stock's 52-week low/high is $0.050500001/$0.490000009.

chart

Regen BioPharma, Inc. (RGBP)

Small Cap Solutions, InvestorTrendz, Insider Financial, TopPennyStockMovers, YCharts, ProTrader, Emerging Growth, SmallCapVoice, Wall Street Mover, TheMicrocapNews, and The OTC Reporter reported earlier on Regen BioPharma, Inc. (RGBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Regen BioPharma, Inc. is a biotechnology company listed on the OTC Markets’ OTCQB. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to quickly advance these technologies through pre-clinical and Phase I/II clinical trials.  Checkpoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Regen BioPharma has its head office in La Mesa, California.

At present, Regen BioPharma is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer. Furthermore, it is focusing  on developing stem cell treatments for aplastic anemia. Fundamentally, the Company is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.  It is currently developing products treating blood disorders employing small molecules and gene silencing (DiffronC) and treating cancer with immunotherapy (dCellVax). 

Regen BioPharma is also modulating vital molecular processes in cancer stem cells by way of its patented molecular targeting approaches (BORIS). In addition, it is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

Regen BioPharma is centering on small molecules to activate and inhibit its main target of interest, NR2F6. The Company is continuing to develop the NR2F6 program in-house before entering into any potential partnerships. It has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

In September, Regen BioPharma reported that its researchers identified a series of small molecule drugs, which inhibit NR2F6 as well as activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors. Therefore, inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, said, "Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner."

Earlier this month, Regen BioPharma reported that its researchers determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). Regen will pursue this testing as a joint venture (JV) with Zander Therapeutics, Inc. Zander Therapeutics has been granted an exclusive license by Regen to develop and commercialize the Company's NR2F6 IP for veterinary applications.

Regen BioPharma, Inc. (RGBP), closed Wednesday's trading session at $0.0015, up 200.00%, on 151,002,769 volume with 414 trades. The average volume for the last 3 months is 8,627,539 and the stock's 52-week low/high is $0.0013/$0.100620001.

chart

The Pulse Beverage Corporation (PLSB)

The Green Baron, Greenbackers, Microcap MarketPlace, Wall St Insider Stocks, Ceocast News, SmallCap Network,  FreeRealTime,  PennyStocksV2, BestStocksDaily, Wall Street Resources, RedChip,  Marketbeat.com, HoleinOneStocks.net, and PennyStockClub reported previously on The Pulse Beverage Corporation (PLSB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

The Pulse Beverage Corporation is the maker of Natural Cabana® Lemonades, Limeades, and Coconut Waters. It introduced Natural Cabana® Lemonade in 2012. Since that time,  it has developed a multi-national distribution system through more than 155 distributors in 49 U.S. States, Canada, Mexico, Panama, Bermuda, and Ireland.  OTCQB-listed, The Pulse Beverage Corporation is headquarterered in Northglenn, Colorado.

The Company’s aim is to be one of the market leaders in the development and marketing of nutritional/functional beverage products, which provide real health benefits to a large portion of the population and are convenient and appealing to consumers.

  Pulse Beverage’s business model uses warehouse direct and key accounts. The Company has secured greater than 20,000 listings for its Lemonades and Limeades and over 5,000 listings for its Coconut Waters with regional and national grocery and convenience chain stores.

The Company offers Natural Cabana® Lemonade/Limeade in seven, low-calorie flavors.  Additionally,  Pulse  offers Natural Cabana® Coconut Water in pineapple and natural flavors.

  Pulse Beverage teams up with major retailers. These retailers include Walmart, Albertsons/Safeway, Food Max, Kroger, Stater Bros, Houchens, 7-Eleven, United C-stores, Kmart, and Weis Markets. Major retailers also include King Kullen, WinCo Foods, Price Less Markets, Hy-Vee Supermarket, Gristede's Foods, Toot n Totem, and Travel America.

Last month, Pulse Beverage announced that it acquired international distribution for its Natural Cabana® Coconut Waters in the People’s Republic of China (PRC) via its new U.S. based distribution partner, Better4U Food & Beverage, Inc.

Better4U has distribution in the PRC and consumer demand for more than 15,000 cases per month worth a minimum of $450K per quarter in Net Revenues for Pulse. In this partnership, Better4U pays for the product up front. This eliminates the credit risks for Pulse.

Furthermore, in March, Pulse announced that it acquired international distribution for its Natural Cabana® Lemonades & Limeades in the Republic of China (Taiwan) via Better4U Food & Beverage. Better4U has distribution in Taiwan and consumer demand for more than 6,500 cases per month worth a minimum of $200K per quarter in additional Net Revenues for Pulse.

The Pulse Beverage Corporation (PLSB), closed Wednesday's trading session at $0.0002, up 100.00%, on 4,6031,668 volume with 18 trades. The average volume for the last 3 months is 6,173,014 and the stock's 52-week low/high is $0.002/$0.194999992.

chart

Talon International, Inc. (TALN)

Liquid Tycoon, Penny Pick Finders, Penny Stock MoneyTrain, Penny Stock Pick Alert, Penny Stock Pick Report, PennyStockProphet, Wall Street Mover, TopPennyStockMovers, Greenbackers, Wallstreetlivechat, OtcWizard, PennyStocks24, SecretStockPromo, StockOnion, Super Nova Stock Picks, WePickPennyStocks, Winning Penny Stock Picks, and Super Hot Penny Stocks reported earlier on Talon International, Inc. (TALN), and we report on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Talon International, Inc. is a top international supplier of zippers, apparel fasteners, trim, and stretch technology products. It supplies these products to manufacturers of fashion apparel, specialty retailers, mass merchandisers, brand licensees, as well as major retailers globally. Established in 1893, Talon is the world’s original zipper brand.

The Company has its head office in Woodland Hills, California.  Moreover, it has offices and facilities across the United States, and in the United Kingdom, Hong Kong, China, Vietnam, India, Indonesia and Bangladesh.

Talon was the inventor of the zipper. It proceeded to pioneer a number of innovations customary in zippers today. Talon’s TekFit® is its newest division. TekFit® has exclusive rights to advanced fabric technologies, which facilitate the addition of mechanical stretch into most standard fabrics.

Talon develops, manufactures, and distributes custom zippers exclusively under its Talon® brand (The World's Original Zipper Since 1893). Furthermore, it designs, develops, manufactures, and distributes complete apparel trim solutions and products; and provides stretch technology for specialty waistbands, shirt collars, and other items all under its trademark and internationally renowned brands, Talon®, and TekFit®.

Last week, Talon International reported financial results for Q2 ended June 30, 2017. Revenues for the three months ended June 30, 2017 were $12.9 million. This represents a drop of $1.6 million, or 10.9 percent, versus the same period in 2016.

Talon Zipper sales were $967,000 lower than the same period in 2016. Talon Trim products, which consist mainly of sales to specialty retail branded customers, dropped by $602,000 versus the same period in 2016.  Both business divisions experienced reduced sales to mass merchandising brand customers and specialty retail brands customers.

Net income for the quarter was $604,000 or $0.01 per share versus $958,000, or $0.01 per share, for the quarter ended June 30, 2016.  Net income for the six months ended June 30, 2017 was $610,000. This represents a drop from $1.0 million in the same period in 2016.

Mr. Larry Dyne, Talon International's Chief Executive Officer, stated, “The soft retail, brick & mortar apparel market negatively affected our second quarter performance.  While the environment may continue to be tough in the near future, we remain focused on our corporate initiatives.  By leveraging existing relationships, we are building on new opportunities, both within our Zipper and Trim products.” 

Talon International, Inc. (TALN), closed Wednesday's trading session at $0.075984, up 136.7103%, on 290 volume with 2 trades. The average volume for the last 3 months is 878 and the stock's 52-week low/high is $0.001099999/$0.115000002.

chart

The QualityStocks Company Corner

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) this morning announced that it has applied to list its common shares on the NASDAQ under the symbol ‘TGOD'. To view the full press release, visit: http://nnw.fm/q07kF.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $2.58, up 7.50%, on 1,287,656 volume with 1,303 trades. The average volume for the last 3 months is 509,873 and the stock's 52-week low/high is $3.56999993/$16.25.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST) is a biotechnology company operating in varied and vibrant market sectors, including hemp cannabidiol (CBD), nutraceuticals, pharmaceuticals and medical-device research and development. Headquartered in Doral, Florida, the company functions by way of diverse, wholly owned subsidiaries centered on developing its role as a global leader in the CBD space. These subsidiaries are also expanding Earth Science Tech’s work in the pharmaceutical and medical-device sectors.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Wednesday's trading session at $0.89, up 11.3892%, on 192,269 volume with 108 trades. The average volume for the last 3 months is 52,200 and the stock's 52-week low/high is $0.600000023/$2.24.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings, Inc. (OTCQB: NGTF), which recently announced its second celebrity custom flavor in a partnership with NFL superstar Richard Sherman, was featured today by the Investorideas.com sector snapshot, examining the influencer power of sports ambassadors partnering with companies to build consumer awareness and drive sales.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Wednesday's trading session at $0.44, up 2.3256%, on 86,890 volume with 19 trades. The average volume for the last 3 months is 187,153 and the stock's 52-week low/high is $0.288599997/$0.446249991.

Recent News

chart

MustGrow Biologics Corp. (CSE: MGRO)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp..

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on the development and commercialization of a suite of natural biopesticides and biofertilizers for the cannabis industry. To view the full article, visit: http://nnw.fm/Smz8H.

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented technology that is a natural biopesticide and biofertilizer for use as a fertilizer, nematicide, pesticide and fungicide. MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The company’s technology provides an all-natural, effective, safe and easy-to-use solution for farmers seeking to raise healthy crops without the use of pesticides.

Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients (http://nnw.fm/Qkz21). For the past 50 years, nematodes have been controlled using chemical nematicides, but the Environmental Protection Agency now restricts or bans many of the chemical?formulations.

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://nnw.fm/3HGuT), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

MustGrow’s technology refines mustard seeds to concentrate the plant’s natural organic compounds that form Allyl isothiocyanate (“AITC”), which serves the plant as a natural defense system against pests and diseases. As a result, MustGrow’s novel product offers first-class performance, is 100 percent natural, and its fertilizer product is listed for organic use by the Organic Materials Review Institute (“OMRI”) under specifications set by the USDA’s National Organic Program.

MustGrow’s initial technology was a granular pre-plant soil biofumigant and biofertilizer containing the active ingredient AITC, a proven nematicide, fungicide and fertilizer. The company has completed 110 independent third-party field trials on fruit and vegetable crops. As a biofertilizer, MustGrow’s product is registered with Health Canada and the EPA in all U.S. states as OMRI-certified. It is also registered for use as a biopesticide by the EPA in key fruit and vegetable growing U.S. states (except California) and with Health Canada. MustGrow is finalizing a new liquid delivery platform with increased concentration of the same active ingredient (AITC) that can be applied through drip lines to meet the demands of today’s growers.

Results of tests completed to date show that MustGrow continues to provide innovative solutions with broad based applications within agriculture. Validated field trial results include:

  • 100 percent control of root-knot nematodes in strawberry crops as compared to methyl bromide
  • 55 percent tomato crop yield increase
  • 95 percent control of Pythium root rot in lettuce fields
  • 70 percent reduction in Verticillium root severity in cucumbers
  • Market Opportunity

Market Opportunity??

MustGrow is also testing the potential application of its technology to the cannabis industry, which is projected to grow to nearly $22 billion in the U.S. by 2020. While there are no uniform guidelines for pesticide use in the cannabis industry, state-by-state regulations in the U.S. do exist which has led to instances of pesticide-tainted cannabis showing up in tested products, leading to recalls and threats of lawsuits. Health Canada recently published regulations for mandatory testing for pesticides in cannabis that are now in effect for all growers.?MustGrow’s?potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Cannabis consumers are increasingly demanding organic products free from chemicals and have shown they are willing to pay a premium for high-quality organic cannabis. MustGrow is currently running cannabis soil trials and is seeking Health Canada approval for use of its product on cannabis.?

Global crop protection is a multibillion-dollar market that is expected to surge over the next five years. Sales of nematicides are set to grow by 33 percent to $1.43 billion by 2022, while biopesticides are projected to leap by 94 percent to an estimated?$9.5 billion by 2022. MustGrow is targeting the global nematicide industry with products that include an innovative pre-plant soil treatment. Solutions for the global biopesticide industry include seed treatment technologies, fungicides and nematicides.??

MustGrow’s groundbreaking technologies use novel plant compounds to provide superior crop protection naturally.

Management Team

President and CEO Corey Giasson is an entrepreneur with more than 20 years in the agriculture, potash, oil and gas, mining and real estate industries.? Mr. Giasson co-founded Rallyemont Energy Inc., a heavy oil company that successfully identified 140 million barrels of recoverable heavy oil, that was sold in 2013 to Husky Energy. He holds an MBA and bachelor’s degree in agricultural economics from the University of Saskatchewan.

Chairman Brad Munro has 20-plus years as a vice president/investments, with a national venture capital firm where he sourced, invested and managed the activity of over 30 companies and invested $150 million. He has served as a director of over 20 public companies and a greater number of private enterprises. Munro is currently director of Secure Energy Services.

COO Colin Betsky is the previous vice president/BioAg at Novozymes, where he was responsible for the company’s BioAg business worldwide. He holds a bachelor’s degree in agriculture from the University of Saskatchewan and has more than 20 years of experience in agricultural chemicals and biologics.

Director Tom Flow is the founder and current president of The Flowr Corporation (TSX.V: FLWR) and Licensed Producer of cannabis in Canada. He founded and built MedReleaf, Canada’s most profitable Licensed Producer which was later acquired by Aurora Cannabis?(TSX: ACB) (NYSE: ACB) for $3.2 billion. Flow is widely recognized for his leadership and expertise in building and operating cannabis cultivation facilities.

Director Matt Kowalski has a tremendous amount of experience in the fruit and vegetable and biologics industries. Under his leadership at Natural Industries, a business focused on biological pest control, the company was awarded five EPA registrations: three biofungicides, a bionematicide, and a bioinsecticide. In November 2012, Kowalski led the strategic sale of Natural Industries to Novozymes BioAg. He is the principal owner of Stronghold Keep Inc., an investment corporation.

CFO Todd Lahti has extensive experience evaluating and managing start-up companies in the biotechnology, agricultural and oil and gas sectors, working directly on financing transactions, mergers and acquisitions, corporate strategy, business development, technology transfer and operations set up. He is a Chartered Financial Analyst and a Chartered Professional Accountant.

MustGrow Biologics Corp. (CSE: MGRO), closed Wednesday's trading session at $0.31, even for the day, on 4,000 volume with 3 trades. The average volume for the last 3 months is 89,396 and the stock's 52-week low/high is $0.0081/$0.14.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://nnw.fm/1jH3I).

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Wednesday's trading session at $7.73, off by 9.5906%, on 84,035 volume with 315 trades. The average volume for the last 3 months is 15,253 and the stock's 52-week low/high is $0.230000004/$0.75.

Recent News

chart

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings Inc. (GRYN) was featured today in the 420 with CNW by CannabisNewsWire. As Oregon struggles with an oversupply of marijuana on its recreational market, it has emerged that the law under which adult-use marijuana was legalized bans the sale of cannabis byproducts out of state. This information was revealed by Caleb Mata, the CEO of Oregon Genetics. Mata raised this issue when he was speaking at a listening event organized in July by the Oregon Liquor Control Commission (OLCC).

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed Wednesday's trading session at $1.43, off by 4.6667%, on 6,600 volume with 6 trades. The average volume for the last 3 months is 16,579 and the stock's 52-week low/high is $0.50999999/$0.850000023.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is intensifying its focus on Europe with the launch of London-based investment platform Supreme Heights. In addition, the company’s previously announced acquisition of privately held, Toronto-based Truverra Inc. is expected to close by August 30. Also today, NetworkNewsWire released a report on the company detailing how SPRWF is actively forming a diverse suite of domestic and global premium-cannabis brands. To view the full article, visit: http://nnw.fm/p3SPG

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Wednesday's trading session at $1.01, off by 3.8095%, on 319,423 volume with 348 trades. The average volume for the last 3 months is 316,270 and the stock's 52-week low/high is $3.5999999/$6.25.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF) is pleased to announce that the AT&T Workforce Manager enterprise application is now available on the Uniden® UV350 in-vehicle phablet through AT&T (NYSE:T).

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Wednesday's trading session at $0.345, off by 1.8771%, on 43,434 volume with 11 trades. The average volume for the last 3 months is 58,081 and the stock's 52-week low/high is $1.75/$7.30155992.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America (OTCQB: MCOA) and joint venture (“JV”) partner Global Hemp Group (CSE: GHG) (OTC: GBHPF) (FRA: GHG) recently announced the start of commercial planting at GHG’s hemp farm in Scio, Oregon, which operates under the name Covered Bridge Acres Ltd. (“CBA”) (http://nnw.fm/oQ0cN). To view the full article, visit: http://nnw.fm/sN4ET.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Wednesday's trading session at $0.004118, off by 1.9524%, on 8,723,913 volume with 151 trades. The average volume for the last 3 months is 9,009,723 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Wednesday's trading session at $0.87, up 2.35%, on 14,180 volume with 18 trades. The average volume for the last 3 months is 68,020 and the stock's 52-week low/high is $1.51520001/$5.20499992.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Wednesday's trading session at $0.15, up 13.1648%, on 40,675 volume with 15 trades. The average volume for the last 3 months is 47,679 and the stock's 52-week low/high is $0.640999972/$3.24640011.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.0108, up 4.3478%, on 4,796,738 volume with 75 trades. The average volume for the last 3 months is 6,404,734 and the stock's 52-week low/high is $0.483999997/$1.38740003.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $0.8999, up 1.6836%, on 43,751 volume with 83 trades. The average volume for the last 3 months is 41,010 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed Wednesday's trading session at $0.20, up 5.2632%, on 37,225 volume with 17 trades. The average volume for the last 3 months is 73,318 and the stock's 52-week low/high is $0.009999999/$0.041000001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.